Infectious disease

EBV BARF1 Peptide Pool

Product number: LB02234

€277.50*

Prices excl. VAT plus shipping costs

Available, delivery time: 1-3 days

sterile and endotoxin free

Delivery Format: The product is supplied freeze dried.

Caution: For research use only. Not for use in humans.

Add to Cart

Description

TechData

Documents

References

Description

Peptide pool of 53 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Secreted protein BARF1 (UniProt: P03225) of Homo sapiens Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4).

One unit allows the stimulation of 2,5 x 10⁸ cells.

TechData

Gene:	BARF1
Delivery:	1-3 days
Counterion:	TFA
No. Peptides:	53 peptides
Amount/Aliquote:	15 nmol (approx. 25µg)/peptide for stimulation of 2,5 x 10⁸ cells
Solubility:	Dissolve in a minimum amount of pure DMSO (40µl) and dilute with water to the desired concentration. Please pay attention that the final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological system.
Protein:	Secreted protein BARF1
UniProt Id:	P03228
Species:	Epstein-Barr virus (EBV; Human herpesvirus 4)
Application:	T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication:	Infectious disease, Cancer, Neuroscience

Documents

Storage and handling of peptides

Probing of membranes with HRP

References

Bosc-Bierne, G et al. „Efficient Quality Control of Peptide Pools by UHPLC and Simultaneous UV and HRMS Detection. Separations 2024, 11, 156. https://doi.org/10.3390/separations11050156

Lin, Yusheng et al. “VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses.” Experimental hematology & oncology vol. 13,1 35. 29 Mar. 2024, doi:10.1186/s40164-024-00501-x

Kim, Sang-Hoon et al. “Omicron BA.2 breakthrough infection elicits CD8+ T cell responses recognizing the spike of later Omicron subvariants.” Science immunology vol. 9,91 (2024): eade6132. doi:10.1126/sciimmunol.ade6132

Controls

Tyrosinase Peptide Pool, human

Pool of 130 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Tyrosinase (Swiss-Prot ID: P14679) of Homo sapiens (Human) for T cell assays (antigen specific T-cell stimulation). One unit allows the stimulation of 2,5 x 108 cells.

€285.00*

Tip

Tetanus Toxin Peptide Pool

Peptide pool of 326 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Tetanus toxin (UniProt ID: P04958) of Clostridium tetani (strain Massachusetts / E88) for T cell assays (e.g. ELISPOT) One unit allows the stimulation of 2,5 x 108 cells.

€475.70*

Tip

HCMVA pp65 Peptide Pool

Peptide Pool of 138 peptides derived from a peptide scan (15mers with 11 aa overlap) through 65 kDa phosphoprotein (pp65) (UniProtKB - P06725) of Human cytomegalovirus (HHV-5). Frequently used as positive control. One unit allows the stimulation of 2,5 x 108 cells. You can find applications and references in our blog: FACS analysis showed: CMV-specific T cells respond to leukemia antigen >

€245.70*

Tyrosinase-related protein 2 Peptide Pool, human

Pool of 127 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through L-dopachrome tautomerase (Tyrosinase-related protein 2) (Swiss-Prot ID: P40126) of Homo sapiens (Human). One unit allows the stimulation of 2,5 x 108 cells.

€285.00*

CEF (classic) Peptide Pool (>95% HPLC)

The CEF peptide pool is a lyophilized mixture of 23 peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus. It consists of defined HLA class I-restricted T cell epitopes from these three viruses. The CEF peptide pool is used as a positive control to stimulate T cells. It induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human CD8 T cells. The peptides of this product are supplied as trifluoracetate salts. One unit allows the stimulation of 2,5 x 108 cells.

€126.30*

Melan-A/MART-1 Peptide Pool, human

Pool of 27 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma antigen recognized by T-cells 1 (MART-1) (UniProt ID: Q16655) of Homo sapiens (Human) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€237.50*

Meso GPI 271-630 Sub Peptide Pool

Pool of 88 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through human Mesothelin (aa271-aa630; UniProt ID: Q13421). One unit allows the stimulation of 2,5 x 108 cells.

€237.50*

JC polyomavirus (VP1) Peptide Pool

Pool of 86 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Major capsid protein VP1 (UniProt ID: P03089) of JC polyomavirus (JCPyV) (JCV) for T cell assays (antigen specific T-cell stimulation). One unit allows the stimulation of 2,5 x 108 cells.

€277.50*

WT1 Peptide Pool, human

Peptide pool of 110 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Wilms tumor protein (WT33) (Swiss-Prot ID: P19544) of Homo sapiens (Human) for T cell assays (e.g. ELISPOT). One unit allows the stimulation of 2,5 x 108 cells. You can find applications and references in our blog: FACS analysis showed: CMV-specific T cells respond to leukemia antigen >

€285.00*

Related Pools

Tyrosinase Peptide Pool, human

€285.00*

AFP Peptide Pool, human

Pool of 150 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Alpha-fetoprotein (Swiss-Prot ID: P02771) of Homo sapiens for T cell assays (e.g. ELISPOT). One unit allows the stimulation of 2,5 x 108 cells.

€380.70*

LAGE1/CTAG2 Peptide Pool, human

Pool of 50 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Cancer/testis antigen 2 (UniProt ID: O75638) of Homo sapiens (Human) for T cell assays (antigen specific T-cell stimulation). One unit allows the stimulation of 2,5 x 108 cells.

€237.50*

BKV (BK-Virus LT) Peptide Pool

Peptide pool of 171 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Large T antigen (UniProtKB - P03071) of BK polyomavirus for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€380.70*

EBV (EBNA-3b) Peptide Pool

Peptide pool of 234 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 4 (EBNA3b) (UniProt ID: Q1HVG4) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€301.30*

HHV6 (U54) Peptide Pool

Pool of 112 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through U54 (UniProt ID: Q9QJ29) of Human herpesvirus 6B for T cell assays (antigen specific T-cell stimulation). One unit allows the stimulation of 2,5 x 108 cells.

€277.50*

HIV control Peptide Pool (95% HPLC)

The peptides of this product are supplied as trifluoracetate salts. This pool consists of 22 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from human immunodeficiency virus (HIV). One unit allows the stimulation of 2,5 x 108 cells.

€237.50*

HBV Protein P Peptide Pool

Peptide pool of 209 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein P (UniProt ID: Q9WRL0) of Hepatitis B virus (HBV). One unit allows the stimulation of 2,5 x 108 cells.

€316.90*

Relatated Petides

EBV LMP2 131-139 (HLA-A*24:02)

Amount in mg: 1 mg

Single peptide (PYLFWLAAI) for stimulation of human EBV LMP2(131-139)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*2402 allele.

€105.00*

EBV EBNA-3A 379-387 (HLA-B*07:02)

Amount in mg: 1 mg

Antigen Peptide EBV EBNA3A HLA-B*07:02 (RPPIFIRRL) for stimulation of human EBV EBNA-3A (379-387) specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0702 allele.

€105.00*

HCMV pp65 417 – 426 (HLA-B*07:02)

Amount in mg: 1 mg

Antigen Peptide CMV pp65 - HLA-B*07:02 (TPRVTGGGAM) for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays. CMV pp65 (415-429) (HLA-B7) is a CEF control peptide that is derived from the Cytomegalovirus (CMV). CMV is capable of infecting a wide range of human cell types, where the body’s primary immune response to CMV is innate, and relies on inflammatory cytokines and costimulatory molecules in order to control the spread of the virus. CMV pp65 (415-429) (HLA-B7) is defined as a CEF control peptide due to its antigenic properties. Clinically, these peptides are suitable epitopes for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-B7 refers to the cell HLA type that this peptide acts on.

€133.20*

HCMV IE-1 316-324 (HLA-A*02:01)

Amount in mg: 1 mg

Antigen Peptide CMV IE1 HLA-A*02:01 (VLEETSVML) stimulation of human CMV IE-1(316-324)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*02:01 allele.

€105.00*

EBV BMLF-1 280-288 (HLA-A*02:01)

Amount in mg: 1 mg

The peptide GLCTLVAML is a linear peptidic epitope (epitope ID 20788) studied as part of the protein „mRNA export factor ICP27 homolog“ (UniProt:Q04360) from Epstein Barr virus (Human herpesvirus 4). The open reading frame „BMLF1“ is coding for this early protein of Epstein Barr virus' lytic cycle. The Epstein Barr virus can cause infectious mononucleosis and in affected patients, CD8+ cytotoxic T lymphocytes react to antigens of the lytic cycle such as BMLF1. In ex vivo assays, the response to BMLF1-280-288 (HLA-A*02:01) in the primary cytotoxic T lymphocyte population was as strong as to the B7-restricted EBNA3A 379-387 epitope, an immunodominant peptide of latent EBV infection. [1] In recent work, EBV BMLF-1 280–288 (GLCTLVAML) was used, for example, to generate recombinant HLA monomers. [2] To do this, scientists let Escherichia coli form recombinant HLA‐A*02:01, ‐A*24:02, and ‐B*07:02 heavy chains. They then generated peptide‐HLA class I complexes through in vitro refolding reactions with E. coli‐derived β2M in the presence of the EBV peptide GLCTLVAML and the RSV peptide NPKASLLSL. The scientists biotinylated the peptide-HLA class I complexes, purified them by gel filtration high performance liquid chromatography, and stored them at −70 °C. Using BMLF-1 280–288 (GLCTLVAML), scientists also investigated the extent to which the novel peptide alarm therapy (PAT) can be applied to the aggressive, treatment-resistant glioblastoma multiforme. [3] Peptide alarm therapy is based on activating virus-specific memory T cells that are common in tumors. These tissue-resident memory T cells (TRM) patrol the tissue and are capable of rapid and effective immune activation upon re-exposure to antigens.To determine whether virus-specific CD8 + T cells are present in human glioblastomas, the scientists used the following immunodominant peptides from common viral infections: GLCTLVAML and CLGGLLTMV from the Epstein-Barr virus, NLVPMVATV from the cytomegalovirus, and GILGFVFTL from the influenza A virus. They were able to detect virus-specific CD8+ T cells in human glioblastomas that express markers for tissue residency. Furthermore, they could reactivate virus-specific memory CD8+ T cells in a murine glioblastoma model by intratumoral delivery of adjuvant-free virus-derived peptides.The literature references can be found under the "References" tab above.

€105.00*

RHAMM 165-173 (HLA-A*02:01)

Amount in mg: 1 mg

RHAMM peptide ILSLELMKL (HLA-A*02:01) for stimulation of human RHAMM -specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*02:01 allele.

€105.00*

HPV16/18 E7 49-57 (H-2 Db)

Amount in mg: 1 mg

RAHYNIVTF is a well-characterized linear epitope derived from residues 49 to 57 of the E7 oncoprotein of Human papillomavirus type 16 (HPV-16, UniProt: P03129), as well as the homologous sequence from HPV-18 (UniProt: P06788). This H-2 Db-restricted peptide is catalogued under epitope ID 53112. Widely recognized for its robust immunogenicity in murine models, RAHYNIVTF has been investigated in over a hundred scientific publications. It has been tested in T cell assays, especially, but also in B cell assay and MHC ligand binding assays. Its widespread use in immunological studies makes it one of the most thoroughly validated HPV E7 epitopes available. This peptide has been evaluated across a diverse range of functional T cell assays, including: Cytotoxicity and T cell activation TNF-α, IL-2, IL-4, IL-10, TGF-β, and granzyme B release Proliferation and degranulation assays Pathogen and tumor burden post-challenge Survival outcomes in viral or tumor models Adoptive transfer and protection assays Due to its proven utility in preclinical tumor models and viral immunity research, RAHYNIVTF serves as a key tool for studying antigen-specific CD8⁺ T cell responses in the context of HPV-related cancer immunotherapy and vaccine development. This peptide is in stock and available for immediate delivery.

€105.00*

DYN-Test

[beta]-Amyloid (1-15)

Aβ (1-15) was used in a study investigating the presence of conformational epitope/s (mimotope/s) on fibrillar amyloid β-protein (1-42). The N-terminal Aβ fragments Aβ1-14, Aβ1-15, and Aβ1-16 are elevated in cell media and in CSF in response to γ-secretase inhibitor treatment. The fragments can serve as biomarkers in clinical studies of the effect of such inhibitors.

From €105.00*